OR WAIT null SECS
June 07, 2025
Video
The ACHIEVE trial found use of spironolcatone was not associated with a statistically significant reduction in cardiovascular death or hospitalization for HF.
Article
An ERA 2025 analysis confirms empagliflozin significantly lowers acute kidney injury risk, reassuring clinicians about its safety in at-risk patients.
June 06, 2025
Podcast
Hosts break down data from the CONFIDENCE trial on the safety and efficacy of finerenone plus empagliflozin in patients with T2D and CKD.
Brendon Neuen, MBBS, PhD, is joined by Rajiv Agarwal, MD, MS to explore the concept of simultaneous initiation of SGLT2i and nsMRA in CKD and T2D.
June 05, 2025
Combination therapy with finerenone and empagliflozin significantly reduces urinary albumin levels in CKD patients.
June 04, 2025
An overview of the 7 presentations included as late-breaking clinical trials at ERA 2025.
June 03, 2025
This FDA News Month in Review provides a round-up of regulatory decisions from May 2025.
June 01, 2025
Brendon Neuen, MBBS, PhD, discusses 3 late breaking clinical trials being presented at ERA 2025.
May 02, 2025
This FDA News Month in Review provides a round-up of regulatory decisions from April 2025.
The month in review spotlights renal FDA news and novel research about CKD and social determinants of health in kidney care.
